Avaliação dos efeitos induzido pelo 2-nitrato-1,3-dibutoxipropano (NDBP) na função vascular em modelo de aterosclerose
Autor(a) principal: | |
---|---|
Data de Publicação: | 2019 |
Tipo de documento: | Dissertação |
Idioma: | por |
Título da fonte: | Biblioteca Digital de Teses e Dissertações da UFPB |
Texto Completo: | https://repositorio.ufpb.br/jspui/handle/123456789/19508 |
Resumo: | Atherosclerosis is a chronic arterial disease of inflammatory and fibroproliferative nature that affects thousands of people a year and is one of the leading causes of death worldwide. Endothelial dysfunction is one of the major detectable changes during the development of atherosclerosis. Characterized by impaired vasodilation and increased vasoconstrictor response, mainly by decreased NO bioavailability and loss of NO / GMPc / PKG signaling. Experimentally, it can be demonstrated by impaired endothelium-dependent relaxation of acetylcholine (Ach) and increased phenylephrine contraction response (Phe). Organic nitrates have been used for years to treat cardiovascular diseases mimicking the role of endogenous NO. However, long-term use of these compounds results in the development of tolerance. In this study an organic nitrate synthesized from glycerin, 2-nitrate-1,3-dibutoxypropane (NDBP) was evaluated. Thus, the aim of the present study was to evaluate the effects of NDBP on vascular function in an atherosclerosis model. Male mice from C57BL / 6 (CT) and apolipoprotein E (apoE-/-) knockouts were used, which respectively received standard diet and Western type atherogenic diet (Rhoster, São Paulo, Brazil), containing 41% of calories in the form of lipids and 1.5% cholesterol from 8 weeks of life over the next 12 weeks. The animals were separated into 3 groups: standard diet C57 control animals, atherogenic diet apoE-/- animals and atherogenic diet apoE-/- animals treated chronically with NDBP. Animal blood was collected for total cholesterol measurement. Animal aortas were collected and processed for organ bath studies or histological evaluation of plaque deposition (Oil-Red staining), ROS production (DHE) and NO (DAF-2DA). Vascular function was assessed by constructing ACh concentration-response curves (100 pM - 30 μM) after phenylephrine pre-contraction (PHE, 10 μM) and PHE concentration-response curves (100 pM - 30 μM). To assess endogenous NO production by indirect method, after pre-contraction with PHE (10μM) the rings were incubated with the non-specific nitric oxide synthase isoform inhibitor L-NAME (100 μM). In order to evaluate the influence of NDBP on vascular function, the rings were incubated with NDBP (10 μM) and vascular function tests were performed. The evaluation of NDBP vasorelaxant activity was performed by NDBP concentration-response curves (100 pM - 30 μM) after PHE pre-contraction (10 μM) in rings with and without endothelium. To assess whether the effect of NPBP on vascular function is dependent on NO or antioxidant activity, the rings were incubated with either NDBP (10μM) plus hydroxycobalamin (HDX, 100μM) or tempol (1μM). In the apoE-/- group that was chronically treated for 14 days, after treatment, vascular function test and baseline NO production were evaluated. The apoE-/- animals showed approximately 12-fold increase in cholesterol levels (TC 58.2 ± 3.6 vs. apoE-/- 704.9 ± 29.9) and marked plaque deposition (CT 0 ± 0 vs. apoE-/- 57 ± 4.9 ). The apoE-/- animals showed marked endothelial dysfunction with impaired ACh relaxation (CT Rmax: 76.7 ± 5.4 and pD2: 7.9 ± 0.3 vs. apoE-/- Rmax: 62.7 ± 5.5 and pD2: 6.7 ± 0.2) and higher response to PHE (CT Rmax: 51.1 ± 9.2 and pD2: 6.8 ± 0.06 vs. apoE-/- Rmax: 82.0 ± 8.3 and pD2: 6.8 ± 0.07). By indirect method, basal NO production was decreased in these animals, demonstrated by the decrease in delta contraction after L-NAME blockade (CT 0.46 ± 0.04 and 45.3 ± 4.1% vs. apoE-/- 0.30 ± 0.01 and 33.2 ± 1.9 %). The same was observed by the direct method using DAF-2DA: apoE-/- animals showed decrease in NO production (CT 131855 ± 15774 vs. apoE-/- 84057 ± 13397). Decreased NO production in apoE-/- animals was reversed following acute NDBP treatment, demonstrated by increased NO concentration measured by DAF-2DA in both groups (CT 196357 ± 18312 vs. apoE-/- 223507 ± 6996). Using the DHE probe it was observed that the apoE-/- animals showed increase in the production of ROS (CT 114036 ± 15280 vs. apoE-/- 166649 ± 13022) and after incubation with NDBP ROS production was decreased in these animals (136043 ± 8281).. NDBP promoted vascular relaxation to the same extent in both groups with absence of endothelium (apoE-/- Rmax: 93 ± 4.1 and pD2: 5.8 ± 0.3; CT Rmax: 102 ± 9.6 and pD2: 5.6 ± 0.4), however in the presence of endothelium apoE-/- animals showed higher sensitivity to the compost (Rmax: 76 ± 11.3 and pD2: 7.2 ± 0.4) when compared to control (Rmax: 69 ± 6.7; pD2: 7.3 ± 0.4). Acute NDBP treatment reversed the ACh relaxation impairment observed in apoE-/- animals (79.4 ± 3.9; pD2: 8.2 ± 0.4) when compared to control (Rmax: 76.0 ± 3.7 pD 2: 7.9 ± 0.2). NDBP-induced vascular function improvement was abolished after joint incubation with HDX (Rmax: 59.9 ± 7.1 and pD2: 6.6 ± 0.3). NDBP-induced relaxation in apoE-/- endothelium-free animal (Rmax: 93 ± 4.1; pD2: 5.8 ± 0.3) was abolished after HDX pre-incubation (Rmax: 0.5 ± 0 6.6, pD2: 6.8 ± 0.9). In order to assess whether NDBP has antioxidant activity, tempol (SOD mimetic) was pre-incubated with or without NDBP. Tempol pre-incubated with NDBP has no potentiated effect (Rmax: 65.1 ± 7.3) when compared to tempol without NDBP (Rmax: 67.4 ± 9.5). ApoE-/- animals treated chronically with NDBP (40mg / kg / in) showed reversal in endothelial dysfunction, demonstrated by an improved relaxation response to ACh when compared to untreated apoE-/- animals (Rmax: 87, 4 ± 3.1; pD2: 7.8 ± 0.1 vs. Rmax: 62.7 ± 5.5; pD2: 6.7 ± 0.2 respectively), equating to the control animals (Rmax: 76.7 ± 5.4; pD2: 7.9 ± 0.3). They also showed an increase in basal NO production demonstrated by the increase in delta contraction when compared to untreated apoE-/- (Δ: 0.39 ± 0.2 vs. Δ: 0.30 ± 0.01 respectively). Thus, it can be concluded that NDBP has beneficial effects on experimental atherosclerosis, being able to reverse endothelial dysfunction by increasing NO bioavailability and its antioxidant effect. |
id |
UFPB_28b3f4efa1b0716d38139978acf8598b |
---|---|
oai_identifier_str |
oai:repositorio.ufpb.br:123456789/19508 |
network_acronym_str |
UFPB |
network_name_str |
Biblioteca Digital de Teses e Dissertações da UFPB |
repository_id_str |
|
spelling |
Avaliação dos efeitos induzido pelo 2-nitrato-1,3-dibutoxipropano (NDBP) na função vascular em modelo de ateroscleroseDisfunção endotelialAteroscleroseÓxido nítricoDoadores de NOEndothelial dysfunctionAtherosclerosisNitric oxideNO donorsCNPQ::CIENCIAS BIOLOGICAS::FISIOLOGIAAtherosclerosis is a chronic arterial disease of inflammatory and fibroproliferative nature that affects thousands of people a year and is one of the leading causes of death worldwide. Endothelial dysfunction is one of the major detectable changes during the development of atherosclerosis. Characterized by impaired vasodilation and increased vasoconstrictor response, mainly by decreased NO bioavailability and loss of NO / GMPc / PKG signaling. Experimentally, it can be demonstrated by impaired endothelium-dependent relaxation of acetylcholine (Ach) and increased phenylephrine contraction response (Phe). Organic nitrates have been used for years to treat cardiovascular diseases mimicking the role of endogenous NO. However, long-term use of these compounds results in the development of tolerance. In this study an organic nitrate synthesized from glycerin, 2-nitrate-1,3-dibutoxypropane (NDBP) was evaluated. Thus, the aim of the present study was to evaluate the effects of NDBP on vascular function in an atherosclerosis model. Male mice from C57BL / 6 (CT) and apolipoprotein E (apoE-/-) knockouts were used, which respectively received standard diet and Western type atherogenic diet (Rhoster, São Paulo, Brazil), containing 41% of calories in the form of lipids and 1.5% cholesterol from 8 weeks of life over the next 12 weeks. The animals were separated into 3 groups: standard diet C57 control animals, atherogenic diet apoE-/- animals and atherogenic diet apoE-/- animals treated chronically with NDBP. Animal blood was collected for total cholesterol measurement. Animal aortas were collected and processed for organ bath studies or histological evaluation of plaque deposition (Oil-Red staining), ROS production (DHE) and NO (DAF-2DA). Vascular function was assessed by constructing ACh concentration-response curves (100 pM - 30 μM) after phenylephrine pre-contraction (PHE, 10 μM) and PHE concentration-response curves (100 pM - 30 μM). To assess endogenous NO production by indirect method, after pre-contraction with PHE (10μM) the rings were incubated with the non-specific nitric oxide synthase isoform inhibitor L-NAME (100 μM). In order to evaluate the influence of NDBP on vascular function, the rings were incubated with NDBP (10 μM) and vascular function tests were performed. The evaluation of NDBP vasorelaxant activity was performed by NDBP concentration-response curves (100 pM - 30 μM) after PHE pre-contraction (10 μM) in rings with and without endothelium. To assess whether the effect of NPBP on vascular function is dependent on NO or antioxidant activity, the rings were incubated with either NDBP (10μM) plus hydroxycobalamin (HDX, 100μM) or tempol (1μM). In the apoE-/- group that was chronically treated for 14 days, after treatment, vascular function test and baseline NO production were evaluated. The apoE-/- animals showed approximately 12-fold increase in cholesterol levels (TC 58.2 ± 3.6 vs. apoE-/- 704.9 ± 29.9) and marked plaque deposition (CT 0 ± 0 vs. apoE-/- 57 ± 4.9 ). The apoE-/- animals showed marked endothelial dysfunction with impaired ACh relaxation (CT Rmax: 76.7 ± 5.4 and pD2: 7.9 ± 0.3 vs. apoE-/- Rmax: 62.7 ± 5.5 and pD2: 6.7 ± 0.2) and higher response to PHE (CT Rmax: 51.1 ± 9.2 and pD2: 6.8 ± 0.06 vs. apoE-/- Rmax: 82.0 ± 8.3 and pD2: 6.8 ± 0.07). By indirect method, basal NO production was decreased in these animals, demonstrated by the decrease in delta contraction after L-NAME blockade (CT 0.46 ± 0.04 and 45.3 ± 4.1% vs. apoE-/- 0.30 ± 0.01 and 33.2 ± 1.9 %). The same was observed by the direct method using DAF-2DA: apoE-/- animals showed decrease in NO production (CT 131855 ± 15774 vs. apoE-/- 84057 ± 13397). Decreased NO production in apoE-/- animals was reversed following acute NDBP treatment, demonstrated by increased NO concentration measured by DAF-2DA in both groups (CT 196357 ± 18312 vs. apoE-/- 223507 ± 6996). Using the DHE probe it was observed that the apoE-/- animals showed increase in the production of ROS (CT 114036 ± 15280 vs. apoE-/- 166649 ± 13022) and after incubation with NDBP ROS production was decreased in these animals (136043 ± 8281).. NDBP promoted vascular relaxation to the same extent in both groups with absence of endothelium (apoE-/- Rmax: 93 ± 4.1 and pD2: 5.8 ± 0.3; CT Rmax: 102 ± 9.6 and pD2: 5.6 ± 0.4), however in the presence of endothelium apoE-/- animals showed higher sensitivity to the compost (Rmax: 76 ± 11.3 and pD2: 7.2 ± 0.4) when compared to control (Rmax: 69 ± 6.7; pD2: 7.3 ± 0.4). Acute NDBP treatment reversed the ACh relaxation impairment observed in apoE-/- animals (79.4 ± 3.9; pD2: 8.2 ± 0.4) when compared to control (Rmax: 76.0 ± 3.7 pD 2: 7.9 ± 0.2). NDBP-induced vascular function improvement was abolished after joint incubation with HDX (Rmax: 59.9 ± 7.1 and pD2: 6.6 ± 0.3). NDBP-induced relaxation in apoE-/- endothelium-free animal (Rmax: 93 ± 4.1; pD2: 5.8 ± 0.3) was abolished after HDX pre-incubation (Rmax: 0.5 ± 0 6.6, pD2: 6.8 ± 0.9). In order to assess whether NDBP has antioxidant activity, tempol (SOD mimetic) was pre-incubated with or without NDBP. Tempol pre-incubated with NDBP has no potentiated effect (Rmax: 65.1 ± 7.3) when compared to tempol without NDBP (Rmax: 67.4 ± 9.5). ApoE-/- animals treated chronically with NDBP (40mg / kg / in) showed reversal in endothelial dysfunction, demonstrated by an improved relaxation response to ACh when compared to untreated apoE-/- animals (Rmax: 87, 4 ± 3.1; pD2: 7.8 ± 0.1 vs. Rmax: 62.7 ± 5.5; pD2: 6.7 ± 0.2 respectively), equating to the control animals (Rmax: 76.7 ± 5.4; pD2: 7.9 ± 0.3). They also showed an increase in basal NO production demonstrated by the increase in delta contraction when compared to untreated apoE-/- (Δ: 0.39 ± 0.2 vs. Δ: 0.30 ± 0.01 respectively). Thus, it can be concluded that NDBP has beneficial effects on experimental atherosclerosis, being able to reverse endothelial dysfunction by increasing NO bioavailability and its antioxidant effect.Conselho Nacional de Pesquisa e Desenvolvimento Científico e Tecnológico - CNPqA aterosclerose é uma doença arterial crônica, de caráter inflamatório e fibroproliferativo que acomete milhares de pessoas ao ano sendo uma das principais causas de morte a nível mundial. A disfunção endotelial é uma das principais alterações detectáveis durante o desenvolvimento da aterosclerose. Caracterizada por vasodilatação prejudicada e aumento da resposta vasoconstritora, principalmente pela diminuição da biodisponibilidade de NO e perda da sinalização da via NO/GMPc/PKG. Experimentalmente, pode ser demonstrada por prejuízo do relaxamento dependente de endotélio à acetilcolina (ACh) e aumento da resposta de contração à fenilefrina (Fen). Os nitratos orgânicos vêm sendo utilizados há anos para tratamento de doenças cardiovasculares mimetizando o papel do NO endógeno. Porém, a utilização desses compostos a longo prazo resulta no desenvolvimento de tolerância. Neste estudo foi avaliado um nitrato orgânico sintetizado a partir da glicerina, o 2-nitrato-1,3-dibutoxipropano (NDBP). Com o objetivo de avaliar os efeitos do NDBP na função vascular em modelo de aterosclerose, utilizou-se camundongos machos, das linhagens C57BL/6 (CT) e nocautes para a apolipoproteína E (apoE-/-), os quais respectivamente receberam dieta padrão e dieta aterogênica Western Type (Rhoster, São Paulo, Brasil), contendo 41% de calorias em forma de lipídios e 1,5% de colesterol a partir de 8 semanas de vida, durante as 12 semana subsequentes. Os animais foram separados em 3 grupos: animais C57 controle com dieta padrão, animais apoE-/- com dieta aterogênica e animais apoE-/- com dieta aterogênica tratados com NDBP crônicamente. O sangue dos animais foi coletado para dosagem de colesterol total. As aortas dos animais foram coletadas e processadas para estudos em banho de órgãos ou avaliação histológica da deposição de placa (coloração Oil-Red), produção de EROs (DHE) e NO (DAF-2DA). A função vascular foi avaliada por meio da construção de curvas concentração-resposta à ACh (100 pM – 30 μM), após pré-contração com fenilefrina (FEN, 10 μM) e curvas concentração-resposta à FEN (100 pM – 30 μM). Para avaliar a produção basal de NO por método indireto, após uma pré-contração com FEN (10μM) os anéis foram incubados com o inibidor não específico da isoformas da óxido nítrico sintase L-NAME (100 μM). Com intuito de avaliar a influência do NDBP sobre a função vascular, os anéis foram incubados com NDBP (10 μM) em seguida foram realizados os testes de função vascular. A avaliação da atividade vasorrelaxante do NDBP foi realizada por meio de curvas concentração-resposta ao NDBP (100 pM – 30 μM) após pré-contração com FEN (10 μM) em anéis com e sem endotélio. Para avaliar se o efeito do NPBP sobre a função vascular é dependente de NO ou de atividade antioxidante, os anéis foram incubados com NDBP (10μM) mais hidroxicobalamina (HDX, 100μM) ou tempol (1μM). No grupo apoE-/- que foi tratado cronicamente por 14 dias, após o tratamento foi realizado teste de função vascular e avaliação da produção basal de NO. Os animais apoE-/- apresentaram incremento de aproximadamente 12 vezes nos níveis de colesterol (CT 58.2±3.6 vs. apoE-/- 704.9±29.9) e marcante deposição de placa (CT 0±0 vs. apoE-/- 57±4.9). Nos grupos sem tratamento crônico observou-se que os animais apoE-/- demonstraram marcante disfunção endotelial com comprometimento no relaxamento a ACh (CT Rmáx: 76.7±5.4 e pD2: 7.9±0.3 vs. apoE-/- Rmáx: 62.7±5.5 e pD2: 6.7±0.2) e maior resposta a FEN (CT Rmáx: 51.1±9.2 e pD2: 6.8±0.06 vs. apoE-/ Rmáx: 82.0±8.3 e pD2: 6.8±0.07). Através de método indireto, a produção de NO endógeno encontrou-se diminuída nesses animais, demostrada pela diminuição no delta de contração após bloqueio com L-NAME (CT 0.46±0.04 e 45.3±4.1% vs. apoE 0.30±0.01 e 33.2±1.9%). O mesmo foi observado através do método direto utilizando DAF-2DA: os animais apoE-/- apresentaram diminuição na produção de NO (CT 131855±15774 vs. apoE-/- 84057±13397). A produção de NO diminuída nos animais apoE-/- foi revertida após incubação com NDBP, demonstrada por aumento na concentração de NO medida por DAF-2DA em ambos os grupos (CT 196357±18312 vs. apoE-/- 223507±6996). Através da utilização da sonda DHE observou-se que os animais apoE-/- apresentaram aumento na produção de EROs (CT 114036±15280 vs. apoE-/- 166649±13022) e após incubação com NDBP a produção de EROs foi diminuída nesses animais (136043±8281). O NDBP promoveu relaxamento vascular na mesma proporção em ambos os grupos na ausência de endotélio (apoE-/- Rmáx: 93±4.1 e pD2: 5.8±0.3; CT Rmáx: 102±9.6 e pD2: 5.6±0.4), porém na presença de endotélio os animais apoE-/- demonstraram maior sensibilidade ao composto (Rmáx: 76±11,3 e pD2: 7,2±0,4) quando comparados ao controle (Rmáx: 69±6,7; pD2: 7,3±0,4). Após incubação com NDBP o prejuízo ao relaxamento a ACh observado nos animais apoE-/- foi revertido (79,4±3,9; pD2: 8,2±0,4) quando comparado ao controle (Rmáx: 76,0±3.7; pD2: 7,9±0,2). A melhora da função vascular induzida pelo NDBP foi abolida após incubação conjunta com HDX (Rmáx: 59,9±7,1 e pD2: 6,6±0,3). O relaxamento induzido pelo NDBP em vasos de animais apoE-/- sem endotélio (Rmáx: 93±4,1; pD2:5,8±0,3) foi abolido após pré-incubação com HDX (Rmáx: 0,5±0,6; pD2: 6,8±0,9). No intuito de avaliar se o NDBP possui atividade antioxidante, o tempol (mimético da SOD) foi pré-incubado com ou sem NDBP. O tempol pré-incubado com NDBP não tem seu efeito potencializado (Rmáx: 65,1±7,3) quando comparado ao tempol sem NDBP (Rmáx: 67,4±9,5). Os animais apoE-/- tratados cronicamente com NDBP (40mg/kg/in), apresentaram reversão no quadro de disfunção endotelial, demonstrado por melhora na resposta de relaxamento a ACh quando comparado aos animais apoE-/- não tratados (Rmáx: 87,4±3,1; pD2: 7,8±0,1 vs. Rmáx: 62,7±5,5; pD2: 6,7±0,2 respectivamente), equiparando aos animais controle (Rmáx:76,7±5,4; pD2: 7,9±0,3). Também apresentaram aumento na produção basal de NO demonstrado pelo aumento no delta de contração quando comparado ao apoE-/- não tratado (Δ: 0,39±0,2 vs. Δ: 0,30±0,01 respectivamente). Desta maneira, é possível concluir que o NDBP apresenta efeitos benéficos na aterosclerose experimental, sendo capaz de reverter o quadro de disfunção endotelial através do aumento da biodisponibilidade de NO e de seu efeito antioxidante.Universidade Federal da ParaíbaBrasilCiências FisiológicasPrograma Multicêntrico de Pós-Graduação em Ciências FisiológicasUFPBBalarini, Camille de Mourahttp://lattes.cnpq.br/0891042053942023Leite, Ericka Garcia2021-02-21T20:27:32Z2019-11-042021-02-21T20:27:32Z2019-08-30info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesishttps://repositorio.ufpb.br/jspui/handle/123456789/19508porhttp://creativecommons.org/licenses/by-nd/3.0/br/info:eu-repo/semantics/openAccessreponame:Biblioteca Digital de Teses e Dissertações da UFPBinstname:Universidade Federal da Paraíba (UFPB)instacron:UFPB2021-08-11T00:10:13Zoai:repositorio.ufpb.br:123456789/19508Biblioteca Digital de Teses e Dissertaçõeshttps://repositorio.ufpb.br/PUBhttp://tede.biblioteca.ufpb.br:8080/oai/requestdiretoria@ufpb.br|| diretoria@ufpb.bropendoar:2021-08-11T00:10:13Biblioteca Digital de Teses e Dissertações da UFPB - Universidade Federal da Paraíba (UFPB)false |
dc.title.none.fl_str_mv |
Avaliação dos efeitos induzido pelo 2-nitrato-1,3-dibutoxipropano (NDBP) na função vascular em modelo de aterosclerose |
title |
Avaliação dos efeitos induzido pelo 2-nitrato-1,3-dibutoxipropano (NDBP) na função vascular em modelo de aterosclerose |
spellingShingle |
Avaliação dos efeitos induzido pelo 2-nitrato-1,3-dibutoxipropano (NDBP) na função vascular em modelo de aterosclerose Leite, Ericka Garcia Disfunção endotelial Aterosclerose Óxido nítrico Doadores de NO Endothelial dysfunction Atherosclerosis Nitric oxide NO donors CNPQ::CIENCIAS BIOLOGICAS::FISIOLOGIA |
title_short |
Avaliação dos efeitos induzido pelo 2-nitrato-1,3-dibutoxipropano (NDBP) na função vascular em modelo de aterosclerose |
title_full |
Avaliação dos efeitos induzido pelo 2-nitrato-1,3-dibutoxipropano (NDBP) na função vascular em modelo de aterosclerose |
title_fullStr |
Avaliação dos efeitos induzido pelo 2-nitrato-1,3-dibutoxipropano (NDBP) na função vascular em modelo de aterosclerose |
title_full_unstemmed |
Avaliação dos efeitos induzido pelo 2-nitrato-1,3-dibutoxipropano (NDBP) na função vascular em modelo de aterosclerose |
title_sort |
Avaliação dos efeitos induzido pelo 2-nitrato-1,3-dibutoxipropano (NDBP) na função vascular em modelo de aterosclerose |
author |
Leite, Ericka Garcia |
author_facet |
Leite, Ericka Garcia |
author_role |
author |
dc.contributor.none.fl_str_mv |
Balarini, Camille de Moura http://lattes.cnpq.br/0891042053942023 |
dc.contributor.author.fl_str_mv |
Leite, Ericka Garcia |
dc.subject.por.fl_str_mv |
Disfunção endotelial Aterosclerose Óxido nítrico Doadores de NO Endothelial dysfunction Atherosclerosis Nitric oxide NO donors CNPQ::CIENCIAS BIOLOGICAS::FISIOLOGIA |
topic |
Disfunção endotelial Aterosclerose Óxido nítrico Doadores de NO Endothelial dysfunction Atherosclerosis Nitric oxide NO donors CNPQ::CIENCIAS BIOLOGICAS::FISIOLOGIA |
description |
Atherosclerosis is a chronic arterial disease of inflammatory and fibroproliferative nature that affects thousands of people a year and is one of the leading causes of death worldwide. Endothelial dysfunction is one of the major detectable changes during the development of atherosclerosis. Characterized by impaired vasodilation and increased vasoconstrictor response, mainly by decreased NO bioavailability and loss of NO / GMPc / PKG signaling. Experimentally, it can be demonstrated by impaired endothelium-dependent relaxation of acetylcholine (Ach) and increased phenylephrine contraction response (Phe). Organic nitrates have been used for years to treat cardiovascular diseases mimicking the role of endogenous NO. However, long-term use of these compounds results in the development of tolerance. In this study an organic nitrate synthesized from glycerin, 2-nitrate-1,3-dibutoxypropane (NDBP) was evaluated. Thus, the aim of the present study was to evaluate the effects of NDBP on vascular function in an atherosclerosis model. Male mice from C57BL / 6 (CT) and apolipoprotein E (apoE-/-) knockouts were used, which respectively received standard diet and Western type atherogenic diet (Rhoster, São Paulo, Brazil), containing 41% of calories in the form of lipids and 1.5% cholesterol from 8 weeks of life over the next 12 weeks. The animals were separated into 3 groups: standard diet C57 control animals, atherogenic diet apoE-/- animals and atherogenic diet apoE-/- animals treated chronically with NDBP. Animal blood was collected for total cholesterol measurement. Animal aortas were collected and processed for organ bath studies or histological evaluation of plaque deposition (Oil-Red staining), ROS production (DHE) and NO (DAF-2DA). Vascular function was assessed by constructing ACh concentration-response curves (100 pM - 30 μM) after phenylephrine pre-contraction (PHE, 10 μM) and PHE concentration-response curves (100 pM - 30 μM). To assess endogenous NO production by indirect method, after pre-contraction with PHE (10μM) the rings were incubated with the non-specific nitric oxide synthase isoform inhibitor L-NAME (100 μM). In order to evaluate the influence of NDBP on vascular function, the rings were incubated with NDBP (10 μM) and vascular function tests were performed. The evaluation of NDBP vasorelaxant activity was performed by NDBP concentration-response curves (100 pM - 30 μM) after PHE pre-contraction (10 μM) in rings with and without endothelium. To assess whether the effect of NPBP on vascular function is dependent on NO or antioxidant activity, the rings were incubated with either NDBP (10μM) plus hydroxycobalamin (HDX, 100μM) or tempol (1μM). In the apoE-/- group that was chronically treated for 14 days, after treatment, vascular function test and baseline NO production were evaluated. The apoE-/- animals showed approximately 12-fold increase in cholesterol levels (TC 58.2 ± 3.6 vs. apoE-/- 704.9 ± 29.9) and marked plaque deposition (CT 0 ± 0 vs. apoE-/- 57 ± 4.9 ). The apoE-/- animals showed marked endothelial dysfunction with impaired ACh relaxation (CT Rmax: 76.7 ± 5.4 and pD2: 7.9 ± 0.3 vs. apoE-/- Rmax: 62.7 ± 5.5 and pD2: 6.7 ± 0.2) and higher response to PHE (CT Rmax: 51.1 ± 9.2 and pD2: 6.8 ± 0.06 vs. apoE-/- Rmax: 82.0 ± 8.3 and pD2: 6.8 ± 0.07). By indirect method, basal NO production was decreased in these animals, demonstrated by the decrease in delta contraction after L-NAME blockade (CT 0.46 ± 0.04 and 45.3 ± 4.1% vs. apoE-/- 0.30 ± 0.01 and 33.2 ± 1.9 %). The same was observed by the direct method using DAF-2DA: apoE-/- animals showed decrease in NO production (CT 131855 ± 15774 vs. apoE-/- 84057 ± 13397). Decreased NO production in apoE-/- animals was reversed following acute NDBP treatment, demonstrated by increased NO concentration measured by DAF-2DA in both groups (CT 196357 ± 18312 vs. apoE-/- 223507 ± 6996). Using the DHE probe it was observed that the apoE-/- animals showed increase in the production of ROS (CT 114036 ± 15280 vs. apoE-/- 166649 ± 13022) and after incubation with NDBP ROS production was decreased in these animals (136043 ± 8281).. NDBP promoted vascular relaxation to the same extent in both groups with absence of endothelium (apoE-/- Rmax: 93 ± 4.1 and pD2: 5.8 ± 0.3; CT Rmax: 102 ± 9.6 and pD2: 5.6 ± 0.4), however in the presence of endothelium apoE-/- animals showed higher sensitivity to the compost (Rmax: 76 ± 11.3 and pD2: 7.2 ± 0.4) when compared to control (Rmax: 69 ± 6.7; pD2: 7.3 ± 0.4). Acute NDBP treatment reversed the ACh relaxation impairment observed in apoE-/- animals (79.4 ± 3.9; pD2: 8.2 ± 0.4) when compared to control (Rmax: 76.0 ± 3.7 pD 2: 7.9 ± 0.2). NDBP-induced vascular function improvement was abolished after joint incubation with HDX (Rmax: 59.9 ± 7.1 and pD2: 6.6 ± 0.3). NDBP-induced relaxation in apoE-/- endothelium-free animal (Rmax: 93 ± 4.1; pD2: 5.8 ± 0.3) was abolished after HDX pre-incubation (Rmax: 0.5 ± 0 6.6, pD2: 6.8 ± 0.9). In order to assess whether NDBP has antioxidant activity, tempol (SOD mimetic) was pre-incubated with or without NDBP. Tempol pre-incubated with NDBP has no potentiated effect (Rmax: 65.1 ± 7.3) when compared to tempol without NDBP (Rmax: 67.4 ± 9.5). ApoE-/- animals treated chronically with NDBP (40mg / kg / in) showed reversal in endothelial dysfunction, demonstrated by an improved relaxation response to ACh when compared to untreated apoE-/- animals (Rmax: 87, 4 ± 3.1; pD2: 7.8 ± 0.1 vs. Rmax: 62.7 ± 5.5; pD2: 6.7 ± 0.2 respectively), equating to the control animals (Rmax: 76.7 ± 5.4; pD2: 7.9 ± 0.3). They also showed an increase in basal NO production demonstrated by the increase in delta contraction when compared to untreated apoE-/- (Δ: 0.39 ± 0.2 vs. Δ: 0.30 ± 0.01 respectively). Thus, it can be concluded that NDBP has beneficial effects on experimental atherosclerosis, being able to reverse endothelial dysfunction by increasing NO bioavailability and its antioxidant effect. |
publishDate |
2019 |
dc.date.none.fl_str_mv |
2019-11-04 2019-08-30 2021-02-21T20:27:32Z 2021-02-21T20:27:32Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/masterThesis |
format |
masterThesis |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://repositorio.ufpb.br/jspui/handle/123456789/19508 |
url |
https://repositorio.ufpb.br/jspui/handle/123456789/19508 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.rights.driver.fl_str_mv |
http://creativecommons.org/licenses/by-nd/3.0/br/ info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
http://creativecommons.org/licenses/by-nd/3.0/br/ |
eu_rights_str_mv |
openAccess |
dc.publisher.none.fl_str_mv |
Universidade Federal da Paraíba Brasil Ciências Fisiológicas Programa Multicêntrico de Pós-Graduação em Ciências Fisiológicas UFPB |
publisher.none.fl_str_mv |
Universidade Federal da Paraíba Brasil Ciências Fisiológicas Programa Multicêntrico de Pós-Graduação em Ciências Fisiológicas UFPB |
dc.source.none.fl_str_mv |
reponame:Biblioteca Digital de Teses e Dissertações da UFPB instname:Universidade Federal da Paraíba (UFPB) instacron:UFPB |
instname_str |
Universidade Federal da Paraíba (UFPB) |
instacron_str |
UFPB |
institution |
UFPB |
reponame_str |
Biblioteca Digital de Teses e Dissertações da UFPB |
collection |
Biblioteca Digital de Teses e Dissertações da UFPB |
repository.name.fl_str_mv |
Biblioteca Digital de Teses e Dissertações da UFPB - Universidade Federal da Paraíba (UFPB) |
repository.mail.fl_str_mv |
diretoria@ufpb.br|| diretoria@ufpb.br |
_version_ |
1801842968833818624 |